By Dr. Evan Lewis, PhD
Last updated: 9 August 2026
Jublia and IodinePure both go on the nail every day, and that is where the similarity ends. Jublia is a prescription azole with Phase 3 trial numbers behind it. IodinePure is a two-ingredient aqueous iodine routine you can start today. Here is what the research shows about each.
Most people who have toenail fungus have had it for years before seeking treatment. When they do, they face a range of options, from expensive prescription topicals to over-the-counter alternatives, with genuinely different tradeoff profiles.
This article compares two of the most evidence-backed options side by side: Jublia (efinaconazole 10%), the prescription topical antifungal that represents the current pharmaceutical standard for topical treatment, and aqueous iodine, the ingredient behind three published papers on onychomycosis and a fundamentally different approach to the same problem.
The goal here is honest comparison, not to dismiss either option, but to give you the information you need to understand what each does, what the evidence says, and which is right for your situation.
What Is Jublia?
Jublia is the brand name for efinaconazole 10% solution, a prescription topical antifungal approved by both the FDA (United States) and Health Canada for the treatment of onychomycosis, fungal nail infection, caused by the dermatophytes Trichophyton rubrum and Trichophyton mentagrophytes, which are responsible for the majority of toenail fungal infections.
Jublia belongs to the azole class of antifungals, the same class that includes the oral fluconazole and the common antifungal clotrimazole. It is applied as a liquid solution directly to the nail surface, where it is designed to penetrate the nail plate and reach the fungal organisms growing beneath.
How Jublia Works
Efinaconazole inhibits an enzyme called lanosterol 14α-demethylase, a critical enzyme in the fungal ergosterol synthesis pathway. Ergosterol is the primary sterol component of the fungal cell membrane; it performs the same structural role in fungi that cholesterol performs in human cell membranes. Without ergosterol synthesis, fungal cell membranes become structurally compromised, leading to cell death.
This is a highly targeted mechanism: it disrupts a specific biochemical pathway unique to fungi. The advantage of a targeted mechanism is precision; the consideration is that targeting a single pathway creates the conditions for resistance to develop, as organisms that develop alternate pathways or mutations in the target enzyme can survive treatment.
Jublia's Own Trial Numbers
Two Phase 3 trials, and the two headline numbers are very different from each other. Reading the CADTH Common Drug Review clinical report for efinaconazole, at week 52 the trials recorded:
- Mycological cure, meaning laboratory-confirmed clearance of the organism: 55.2% and 53.4%
- Complete cure, meaning a clear nail and no detectable fungus at the same time: 17.8% and 15.2%
Those numbers require context to be read properly. Mycological cure is the earlier, more achievable endpoint, because complete visual clearance of the nail lags many months behind clearing the organism, for reasons of nail growth covered further down. The mycological figure is meaningfully better than earlier topicals such as ciclopirox, and it is the current topical standard. The complete-cure figure is the one most patients are actually picturing when they start, and it is the smaller of the two by a wide margin.
The Cost of a Jublia Course
That depends on how many nails are involved. CADTH published a separate Pharmacoeconomic Review Report for efinaconazole in 2019, and it records the drug as available in 8 mL bottles at a submitted price of $89.04 per bottle. Over the 48-week course used in the manufacturer's pivotal trials, that report models two bottles, $178, for a patient with a single affected great toenail, and five bottles, $445, for a patient with one affected great toenail and three smaller ones, which was the median of four affected toenails per patient in those trials.
Those are the manufacturer's submitted 2019 price and CADTH's modelled scenarios rather than a current shelf price, so check with your own pharmacy. Treatment runs 48 weeks of daily application, and it requires a prescription, which requires a podiatrist or dermatologist visit. With extended health benefits, cost may be substantially reduced or covered. Without, it is a real practical barrier.
Who Jublia Is Right For
Jublia is best suited for patients with moderate to severe nail fungus who have not achieved results with OTC approaches, who are not candidates for oral terbinafine (due to liver concerns, drug interactions, or personal preference against systemic medication), and who have insurance coverage that makes the cost manageable. It is an FDA and Health Canada-approved treatment with a substantial clinical trial evidence base. For the right patient in the right situation, it is a well-supported choice.
What Is IodinePure Aqueous Iodine?
IodinePure's EZ Clear Nails is an aqueous iodine solution, elemental iodine stabilised in distilled water, formulated for daily topical application to the nail. It contains two ingredients: iodine and distilled water. It is listed with Health Canada as a cosmetic. It does not require a prescription and is available directly.
Aqueous iodine is not a new compound repurposed for nail care. Iodine has been used as an antimicrobial in clinical settings since the 1800s, one of the longest clinical safety records of any topical agent. Its activity against fungi, bacteria, and other microorganisms is well-documented across this history.
How Aqueous Iodine Works
Iodine works through multiple simultaneous mechanisms, which distinguishes it from the single-enzyme-target approach of azole antifungals. Reviewing the evidence in Antimicrobial Agents and Chemotherapy, Lepelletier and colleagues describe iodine as rapidly penetrating microorganisms and oxidising key proteins, nucleotides and fatty acids, and report no observed link between iodine use and the development of resistance.
That breadth is the point. For iodine to be resisted, an organism would need defences against several simultaneous attack vectors at once, a considerably higher evolutionary bar than a mutation at a single target enzyme. That is a statement about the ingredient in the research literature, not a performance promise about any bottle on a shelf.
What the Research on Iodine Says
Three published papers, all small: two single-patient case reports and one 13-patient chart review. That is a genuinely different tier of evidence from a registration trial programme, and it is worth being precise about.
Davidson R, CMAJ 2006 — a retired physician applied 2.5% iodine tincture daily to his own affected toenail. Normal-looking nail appeared at the proximal end within about two weeks and the affected area moved outward from there. Total cost, $3.27. The author was explicit that this was a single case. PMC1569938.
Capriotti K and Capriotti JA, Int Med Case Rep J 2015 — one patient with severe, treatment-resistant onychomycosis applied 1% povidone-iodine in a 44% DMSO vehicle twice daily. At the 24-week visit the authors report the nail had cleared with a negative fungal culture. One patient. PMC4599634.
Capriotti K, Stewart KP, Pelletier JP, Capriotti J, Clin Res Trials 2016 — a retrospective chart review of 13 patients on the same 1% povidone-iodine in aqueous DMSO twice daily. At the 24-week point, 8 of 13 patients (62%) had negative culture results.
These are findings about iodine as an ingredient, in the preparations each research group used. They are case reports and a chart review rather than a registration trial programme, which is a difference in the type of evidence rather than a verdict on either option. Jublia's numbers come from a pharmaceutical approval process; iodine's come from the academic literature.
Who IodinePure Is Right For
Aqueous iodine is best suited for patients with mild to moderate nail fungus as a first-line daily routine; patients who prefer a natural, non-prescription approach; patients without insurance coverage for Jublia for whom the cost barrier is significant; and as a daily maintenance routine following a course of prescription treatment. It is also a reasonable choice for anyone who wants to begin a consistent daily protocol while they decide on a longer-term treatment approach.
How Do the Two Compare Head to Head?
Jublia has the stronger evidence tier and the higher documented numbers. Iodine has the simpler formula, no prescription, and a cost profile that makes a year of daily use realistic. They are not really the same kind of thing.
| Feature | Jublia (Efinaconazole 10%) | IodinePure EZ Clear Nails |
|---|---|---|
| Mechanism | Inhibits lanosterol 14α-demethylase (single enzyme target); disrupts ergosterol synthesis | Multi-mechanism oxidative disruption of microbial proteins, nucleotides and fatty acids |
| Clinical Evidence | Phase 3 RCTs (FDA/Health Canada registration trials); high-quality pharmaceutical-level evidence | Published case reports and a 13-patient chart review (Davidson 2006; Capriotti 2015; Capriotti 2016) |
| Documented rates | Mycological cure 55.2% / 53.4%; complete cure 17.8% / 15.2% at week 52 (CADTH) | Not directly comparable; two case reports and one 13-patient chart review (8 of 13 culture-negative at 24 weeks) |
| Cost | CADTH pharmacoeconomic review (2019): submitted price $89.04 per 8 mL bottle; modelled 48-week course $178 for one affected toenail, $445 for four. Check your own pharmacy | Significantly more affordable; no prescription visit required |
| Prescription Required | Yes, requires podiatrist or dermatologist visit | No, available directly without prescription |
| Staining | No staining | No staining (non-staining aqueous formulation) |
| Ease of Daily Use | Applicator brush; daily application to nail; drying time required | Soak plus spray; two-ingredient formula; reaches under the nail edge and into the folds |
| Resistance Potential | Azole resistance documented in clinical literature for class | Lepelletier 2020 reports no observed link between iodine use and resistance development |
| Health Canada Status | Approved as prescription drug (DIN) | Listed as a cosmetic |
| Ingredient Count | Multiple (active + polymer carrier, penetration enhancers, preservatives) | Two (iodine and distilled water) |
Why Does Compliance Decide the Outcome?
Because both options need to be applied every day for the better part of a year, and the nail itself sets a pace no product can beat. The treatment you will still be using in month nine usually outperforms the stronger one you abandoned in week eight.
Jublia requires 48 weeks, nearly a full year. Aqueous iodine protocols are recommended for a minimum of 90 days to start. Both are working toward the same underlying goal: consistent topical exposure to the nail and nail unit, day after day, for long enough that the infected nail tissue grows out and is replaced.
Here is the number that governs all of it. Toenails grow at roughly 1.62 mm per month (Yaemsiri and colleagues, JEADV 2010, PubMed 19744178). The 3 mm figure quoted in most articles is the fingernail rate, and it is roughly double. A great toenail is 20 to 25 mm from base to tip, so a substantially affected nail needs 12 to 18 months of growth to clear visually, regardless of how well the treatment clears the organism. That is worth sitting with: even Jublia's own 48-week course is shorter than the time the nail itself needs. There is no shortcut around the pace of nail biology.
There is a second reason consistency slips, and it is not laziness. In a 250-patient study of topical treatment for another skin condition, Sevimli Dikicier found 45.6% of patients stopped their topical early, and 37.7% of those stopped because of irritation, redness, scaling, itching or stinging. Whatever is in the bottle has to be liveable, every day, for months.
What this means practically is that compliance is not a secondary consideration. It is often the primary variable separating patients who achieve clearance from those who do not. And it is why cost, accessibility and how a product feels on skin are not merely commercial questions. They are clinical ones.
What Do I Recommend?
Start with iodine for mild to moderate nails, and have the prescription conversation for anything more advanced or anything that has already failed a consistent OTC routine.
For mild to moderate toenail fungus in patients approaching treatment for the first time, I consider aqueous iodine a rational starting point. Three published papers sit behind the ingredient, the mechanism is well described in the literature, the cost and accessibility profile makes consistent daily use achievable, and the safety record going back to the 1800s is as well documented as any topical compound in medicine.
For moderate to severe infections, for infections that have not responded to a consistent OTC protocol, or for patients who want the highest-documented-efficacy topical option, a conversation with a podiatrist about prescription options, including Jublia and oral terbinafine, is the appropriate next step. These are not competing recommendations: many patients use aqueous iodine as a daily maintenance routine alongside or following prescription treatment.
The honest position is that Jublia has stronger clinical trial evidence by virtue of the pharmaceutical registration trial process, and oral terbinafine has higher documented cure rates than either topical option. Aqueous iodine has a genuine evidence base, meaningful practical advantages, and a different set of tradeoffs. The right choice depends on severity, patient circumstances, insurance coverage, and personal preference.
Already Using Jublia? Here's How to Add IodinePure
If you are on a Jublia course and want to add an iodine routine, timing matters, because iodine can break down the efinaconazole film if the two are applied together. Our guide on how to use IodinePure alongside Jublia walks through the simple morning-and-night schedule that keeps them from working against each other. If you are considering clinic light therapy instead, see how to fit IodinePure around Toe FX treatments, and for the full landscape of choices, our 2026 guide to toenail fungus treatments in Canada.
Frequently Asked Questions
Is there an alternative to Jublia?
Yes. The prescription alternatives to Jublia for toenail fungus include oral terbinafine (Lamisil), the highest-efficacy option for moderate to severe infections, and ciclopirox (Penlac), an older prescription topical lacquer. Non-prescription alternatives with published evidence behind the ingredient include aqueous iodine formulations. For patients for whom cost is a significant factor, the combination of an aqueous iodine daily protocol and a podiatrist discussion about oral options is a reasonable alternative pathway.
Is IodinePure as effective as Jublia?
The two have never been compared head to head, so no honest answer exists in the form the question expects. Jublia has Phase 3 data: 55.2% and 53.4% mycological cure, and 17.8% and 15.2% complete cure, at week 52. Iodine has three published papers: two single-patient case reports and a 13-patient chart review in which 8 of 13 were culture-negative at 24 weeks. Those are different tiers of evidence. What can be said is that they work through different mechanisms and their practical tradeoffs, cost, accessibility, ingredient profile and resistance picture, differ in ways that matter to different people.
Can I use iodine instead of Jublia?
For mild to moderate infections and as a first-line approach before prescription treatment, yes. Aqueous iodine has published evidence behind the ingredient and is a reasonable starting protocol. If you have moderate to severe nail fungus, multiple nails involved, or you have already tried a consistent OTC protocol without response, discussing prescription options with a podiatrist or dermatologist is the more appropriate step. The two are not mutually exclusive: some patients use aqueous iodine as a daily maintenance routine alongside or following prescription treatment.
How long before a toenail actually looks different?
Longer than most people budget for, and this is the single most common reason people quit. Toenails grow about 1.62 mm a month, and a great toenail is 20 to 25 mm from base to tip, so a completely replaced nail is a 12 to 18 month project. New growth at the base is usually visible somewhere around 60 to 90 days, and that band of clearer new nail, rather than the old damaged part, is what you judge progress on. Any product promising a transformed nail in weeks is promising something nails cannot physically do.
How does aqueous iodine compare to prescription antifungals?
They differ in mechanism (multi-pathway oxidative disruption versus targeted enzyme inhibition), evidence level (published case reports and a chart review versus pharmaceutical registration trials), cost, and accessibility. The tradeoff is that prescription options, particularly oral terbinafine, have higher documented cure rates in controlled trial conditions for moderate to severe infections. For mild infections and people seeking a natural, accessible, non-prescription option, aqueous iodine is a reasonable choice. Severity, circumstances and personal preference should decide it.
What is the most affordable option with published evidence behind it?
Aqueous iodine formulations, including IodinePure EZ Clear Nails, are the most affordable option with published papers behind the ingredient. No prescription is required and no specialist visit is needed to start. Where oral terbinafine is medically appropriate and covered by a provincial formulary or benefits plan, it can also be relatively affordable. Discuss coverage with your pharmacy and benefits provider.
Start the 90-Day Protocol
IodinePure EZ Clear Nails delivers stabilised aqueous iodine to the nail in a non-staining, two-ingredient formula, built around a soak that reaches under the nail edge and into the folds plus a twice-daily spray. The three published papers described above tested preparations the researchers made themselves, not this or any other retail product. No prescription required. Affordable enough that daily use for 90 days is actually achievable.
References
- CADTH Common Drug Review. Clinical review report: efinaconazole (Jublia). NCBI Bookshelf NBK543976 (source for the cure-rate figures)
- CADTH Common Drug Review. Pharmacoeconomic review report: efinaconazole (Jublia). 2019. NCBI Bookshelf NBK543376 (source for the price and course-cost figures)
- Lepelletier D, Maillard JY, Pozzetto B, Simon A. Povidone iodine: properties, mechanisms of action, and role in infection control and Staphylococcus aureus decolonization. Antimicrob Agents Chemother. 2020. PMC7449185
- Davidson R. An economical cure. CMAJ. 2006. PMC1569938
- Capriotti K, Capriotti JA. Onychomycosis treated with a dilute povidone-iodine/DMSO preparation. Int Med Case Rep J. 2015. PMC4599634
- Capriotti K, Stewart KP, Pelletier JP, Capriotti J. Treatment of onychomycosis with dilute topical povidone-iodine in a dimethylsulfoxide solvent system. Clin Res Trials. 2016. Full text
- Yaemsiri S, Hou N, Slining MM, He K. Growth rate of human fingernails and toenails in healthy American young adults. J Eur Acad Dermatol Venereol. 2010. PubMed 19744178
- Sevimli Dikicier B. Topical treatment of acne vulgaris: efficiency, side effects, and adherence rate. J Int Med Res. 2019;47(7):2987-2992. PubMed 31122106
